{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T12:41:48Z","timestamp":1792759308515,"version":"4.5.0"},"reference-count":58,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,2,4]],"date-time":"2021-02-04T00:00:00Z","timestamp":1612396800000},"content-version":"vor","delay-in-days":369,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100015237","name":"Medicines Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015237","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016619","name":"MyoKardia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["ZE 1109\/1-1"],"award-info":[{"award-number":["ZE 1109\/1-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004191","name":"Novo Nordisk","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005788","name":"Medizinische Universit\u00e4t Wien","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005788","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American College of Cardiology"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1016\/j.jacc.2019.11.036","type":"journal-article","created":{"date-parts":[[2020,1,27]],"date-time":"2020-01-27T15:59:28Z","timestamp":1580140768000},"page":"435-447","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":100,"title":["Clinical Benefit of Cardiorenal Effects of Sodium-Glucose Cotransporter 2\u00a0Inhibitors"],"prefix":"10.1016","volume":"75","author":[{"given":"Thomas A.","family":"Zelniker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugene","family":"Braunwald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacc.2019.11.036_bib1","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1002\/jlac.18350150210","article-title":"Analyse des phloridzins","volume":"15","author":"Petersen","year":"1835","journal-title":"Annalen der Pharmacie"},{"key":"10.1016\/j.jacc.2019.11.036_bib2","first-page":"531","article-title":"\u00dcber k\u00fcnstlichen diabetes","volume":"22","author":"von Mering","year":"1886","journal-title":"Centralblatt fur die medizinische Wissenschaft"},{"key":"10.1016\/j.jacc.2019.11.036_bib3","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.ejmech.2019.07.032","article-title":"Design, synthesis and biological evaluation of 6-deoxy O-spiroketal C-arylglucosides as novel renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetes","volume":"180","author":"Wang","year":"2019","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.jacc.2019.11.036_bib4","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(18)32590-X","article-title":"SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials","volume":"393","author":"Zelniker","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2019.11.036_bib5","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2019.11.036_bib6","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.jacc.2019.11.031","article-title":"Mechanisms of cardiorenal effects of sodium-glucose cotransporter 2 inhibitors: JACC state-of-the-art review","volume":"75","author":"Zelniker","year":"2020","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2019.11.036_bib7","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2019.11.036_bib8","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2019.11.036_bib9","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2019.11.036_bib10","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2019.11.036_bib11","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1161\/CIRCULATIONAHA.118.037778","article-title":"Empagliflozin reduced mortality and hospitalization for heart failure across the spectrum of cardiovascular risk in the EMPA-REG OUTCOME trial","volume":"139","author":"Fitchett","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2019.11.036_bib12","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1093\/eurheartj\/ehv728","article-title":"Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME trial","volume":"37","author":"Fitchett","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2019.11.036_bib13","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.jacc.2017.11.022","article-title":"Empagliflozin reduces mortality and hospitalization for heart failure in patients with or without a history of myocardial infarction or stroke at baseline (abstr)","volume":"71","author":"Fitchett","year":"2018","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2019.11.036_bib14","doi-asserted-by":"crossref","first-page":"e42","DOI":"10.2337\/dc18-1959","article-title":"Empagliflozin and cardiovascular outcomes in patients with type 2 diabetes and left ventricular hypertrophy: a subanalysis of the EMPA-REG OUTCOME trial","volume":"42","author":"Verma","year":"2019","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jacc.2019.11.036_bib15","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1161\/CIRCULATIONAHA.118.038339","article-title":"Empagliflozin is associated with a lower risk of post-acute heart failure rehospitalization and mortality","volume":"139","author":"Savarese","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2019.11.036_bib16","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1161\/CIRCULATIONAHA.119.039996","article-title":"Dapagliflozin and cardiovascular outcomes in patients with type 2 diabetes and prior myocardial infarction: a sub-analysis from DECLARE TIMI-58 Trial","volume":"139","author":"Furtado","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2019.11.036_bib17","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1016\/j.jacc.2018.08.1038","article-title":"Fourth universal definition of myocardial infarction (2018)","volume":"72","author":"Thygesen","year":"2018","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2019.11.036_bib18","doi-asserted-by":"crossref","first-page":"2591","DOI":"10.1161\/CIRCULATIONAHA.119.040057","article-title":"Effects of canagliflozin on heart failure outcomes associated with preserved and reduced ejection fraction in type 2 diabetes","volume":"139","author":"Figtree","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2019.11.036_bib19","doi-asserted-by":"crossref","first-page":"2528","DOI":"10.1161\/CIRCULATIONAHA.119.040130","article-title":"Effect of dapagliflozin on heart failure and mortality in type 2 diabetes mellitus","volume":"139","author":"Kato","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2019.11.036_bib20","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1161\/CIRCULATIONAHA.119.042375","article-title":"Effect of empagliflozin on left ventricular mass in patients with type 2 diabetes and coronary artery disease: the EMPA-HEART CardioLink-6 Randomized Clinical Trial","volume":"140","author":"Verma","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2019.11.036_bib21","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/j.jacc.2017.06.016","article-title":"Effects of canagliflozin on cardiovascular biomarkers in older adults with type 2 diabetes","volume":"70","author":"Januzzi","year":"2017","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2019.11.036_bib22","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1161\/CIRCULATIONAHA.119.042929","article-title":"Dapagliflozin effects on biomarkers, symptoms, and functional status in patients with heart failure with reduced ejection fraction: the DEFINE-HF trial","volume":"140","author":"Nassif","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2019.11.036_bib23","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1002\/ejhf.1432","article-title":"A\u00a0trial to evaluate the effect of the sodium-glucose co-transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA-HF)","volume":"21","author":"McMurray","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jacc.2019.11.036_bib24","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1002\/ejhf.1548","article-title":"The Dapagliflozin And Prevention of Adverse-outcomes in Heart\u00a0Failure (DAPA-HF) trial: baseline characteristics","volume":"21","author":"McMurray","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jacc.2019.11.036_bib25","doi-asserted-by":"crossref","first-page":"2755","DOI":"10.1681\/ASN.2018010103","article-title":"Empagliflozin and kidney function decline in patients with type 2 diabetes: a slope analysis from the EMPA-REG OUTCOME trial","volume":"29","author":"Wanner","year":"2018","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.jacc.2019.11.036_bib26","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa1515920","article-title":"Empagliflozin and progression of kidney disease in type 2 diabetes","volume":"375","author":"Wanner","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2019.11.036_bib27","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/S2213-8587(18)30141-4","article-title":"Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS program randomised clinical trials","volume":"6","author":"Perkovic","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.jacc.2019.11.036_bib28","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/S2213-8587(19)30180-9","article-title":"Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial","volume":"7","author":"Mosenzon","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.jacc.2019.11.036_bib29","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/S2213-8587(19)30256-6","article-title":"SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis","volume":"7","author":"Neuen","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.jacc.2019.11.036_bib30","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.118.005875","article-title":"Empagliflozin improves kidney outcomes in patients with or without heart failure","volume":"12","author":"Butler","year":"2019","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jacc.2019.11.036_bib31","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1161\/CIRCULATIONAHA.118.035901","article-title":"Cardiovascular and renal outcomes with canagliflozin according to baseline kidney function","volume":"138","author":"Neuen","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2019.11.036_bib32","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1161\/CIRCULATIONAHA.117.028268","article-title":"Empagliflozin and clinical outcomes in patients with type 2 diabetes mellitus, established cardiovascular disease, and chronic kidney disease","volume":"137","author":"Wanner","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2019.11.036_bib33","doi-asserted-by":"crossref","first-page":"2394","DOI":"10.1111\/dom.13820","article-title":"Sodium glucose cotransporter 2 inhibitors and risk of genital mycotic and urinary tract infections: a population-based study of older women and men with diabetes","volume":"21","author":"Lega","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jacc.2019.11.036_bib35","doi-asserted-by":"crossref","first-page":"764","DOI":"10.7326\/M19-0085","article-title":"Fournier gangrene associated with sodium-glucose cotransporter-2 inhibitors: a review of spontaneous postmarketing cases","volume":"170","author":"Bersoff-Matcha","year":"2019","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jacc.2019.11.036_bib36","doi-asserted-by":"crossref","first-page":"e47","DOI":"10.2337\/dc17-1721","article-title":"SGLT2 inhibitor-associated euglycemic diabetic ketoacidosis: a South Australian clinical case series and Australian spontaneous adverse event notifications","volume":"41","author":"Meyer","year":"2018","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jacc.2019.11.036_bib37","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1007\/s00125-019-4839-8","article-title":"Effects of canagliflozin on amputation risk in type 2 diabetes: the CANVAS program","volume":"62","author":"Matthews","year":"2019","journal-title":"Diabetologia"},{"key":"10.1016\/j.jacc.2019.11.036_bib38","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.metabol.2019.04.008","article-title":"Sodium-glucose co-transporter-2 inhibitors (SGLT2i) use and risk of amputation: an expert panel overview of the evidence","volume":"96","author":"Katsiki","year":"2019","journal-title":"Metabolism"},{"key":"10.1016\/j.jacc.2019.11.036_bib39","doi-asserted-by":"crossref","first-page":"80","DOI":"10.7326\/L19-0320","article-title":"Fracture risk after initiation of use of canagliflozin: a cohort study","volume":"171","author":"Fralick","year":"2019","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jacc.2019.11.036_bib40","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.2337\/dc15-1730","article-title":"Efficacy and safety of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to insulin in patients with type 1 diabetes","volume":"38","author":"Henry","year":"2015","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jacc.2019.11.036_bib41","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1016\/S2213-8587(17)30308-X","article-title":"Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24\u00a0week results from a multicentre, double-blind, phase 3, randomised controlled trial","volume":"5","author":"Dandona","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.jacc.2019.11.036_bib42","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.2337\/dc18-0623","article-title":"Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (the DEPICT-2 study): 24-week results from a randomized controlled trial","volume":"41","author":"Mathieu","year":"2018","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jacc.2019.11.036_bib43","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.2337\/dc18-1749","article-title":"Empagliflozin as adjunctive to insulin therapy in type 1 diabetes: the EASE trials","volume":"41","author":"Rosenstock","year":"2018","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jacc.2019.11.036_bib44","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1056\/NEJMoa1708337","article-title":"Effects of sotagliflozin added to insulin in patients with type 1 diabetes","volume":"377","author":"Garg","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2019.11.036_bib45","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1007\/s00125-018-4671-6","article-title":"SGLT inhibitor adjunct therapy in type 1 diabetes","volume":"61","author":"McCrimmon","year":"2018","journal-title":"Diabetologia"},{"key":"10.1016\/j.jacc.2019.11.036_bib46","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1111\/dom.13260","article-title":"Sodium-glucose co-transporter-2 inhibitors as add-on therapy to insulin for type 1 diabetes mellitus: systematic review and meta-analysis of randomized controlled trials","volume":"20","author":"Yamada","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jacc.2019.11.036_bib47","doi-asserted-by":"crossref","first-page":"2552","DOI":"10.2337\/dc18-1087","article-title":"Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes: the DEPICT-1 52-week study","volume":"41","author":"Dandona","year":"2018","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jacc.2019.11.036_bib48","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1089\/dia.2019.0157","article-title":"Sotagliflozin added to optimized insulin therapy leads to lower rates of clinically relevant hypoglycemic events at any HbA1c at 52\u00a0weeks in adults with type 1 diabetes","volume":"21","author":"Danne","year":"2019","journal-title":"Diabetes Technol Ther"},{"key":"10.1016\/j.jacc.2019.11.036_bib49","doi-asserted-by":"crossref","first-page":"3200","DOI":"10.1016\/j.jacc.2018.09.020","volume":"72","author":"Das","year":"2018","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2019.11.036_bib50","doi-asserted-by":"crossref","first-page":"2669","DOI":"10.2337\/dci18-0033","article-title":"Management of hyperglycemia in type 2 diabetes, 2018: a consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"41","author":"Davies","year":"2018","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jacc.2019.11.036_bib51","first-page":"S90","article-title":"9. Pharmacologic approaches to glycemic treatment: Standards of Medical Care in Diabetes\u20142019","volume":"42 Suppl 1","year":"2019","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jacc.2019.11.036_bib52","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1016\/j.jacc.2019.03.009","article-title":"2019 ACC\/AHA guideline on the primary prevention of cardiovascular disease: executive summary: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"74","author":"Arnett","year":"2019","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2019.11.036_bib53","doi-asserted-by":"crossref","first-page":"2354","DOI":"10.1111\/dom.13819","article-title":"Use of sodium-glucose co-transporter-2 inhibitors in patients with type 2 diabetes mellitus and multiple cardiovascular risk factors: an Asian perspective and expert recommendations","volume":"21","author":"Deerochanawong","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jacc.2019.11.036_bib54","doi-asserted-by":"crossref","first-page":"3215","DOI":"10.1093\/eurheartj\/ehz687","article-title":"2019 ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD","volume":"40","author":"Cosentino","year":"2019","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2019.11.036_bib55","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1161\/CIRCULATIONAHA.119.042685","article-title":"Heart failure risk stratification and efficacy of sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes mellitus","volume":"140","author":"Berg","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2019.11.036_bib56","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1080\/14656566.2016.1232395","article-title":"SGLT2 inhibitors in the pipeline for the treatment of diabetes mellitus in Japan","volume":"17","author":"Ito","year":"2016","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.jacc.2019.11.036_bib57","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/dom.13630","article-title":"What does sodium-glucose co-transporter 1 inhibition add: prospects for dual inhibition","volume":"21 Suppl 2","author":"Dominguez Rieg","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jacc.2019.11.036_bib58","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ahj.2018.08.016","article-title":"Design and baseline characteristics of the eValuation of ERTugliflozin effIcacy and Safety CardioVascular outcomes trial (VERTIS-CV)","volume":"206","author":"Cannon","year":"2018","journal-title":"Am Heart J"},{"key":"10.1016\/j.jacc.2019.11.036_bib59","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.diabet.2019.07.007","article-title":"Type 2 diabetes: Why should diabetologists and cardiologists work more closely together?","volume":"45","author":"Valensi","year":"2019","journal-title":"Diabetes Metab"}],"container-title":["Journal of the American College of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109719385195?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109719385195?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T13:29:26Z","timestamp":1760016566000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0735109719385195"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":58,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["S0735109719385195"],"URL":"https:\/\/doi.org\/10.1016\/j.jacc.2019.11.036","relation":{},"ISSN":["0735-1097"],"issn-type":[{"value":"0735-1097","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical Benefit of Cardiorenal Effects of Sodium-Glucose Cotransporter 2\u00a0Inhibitors","name":"articletitle","label":"Article Title"},{"value":"Journal of the American College of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacc.2019.11.036","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 by the American College of Cardiology Foundation. Published by Elsevier.","name":"copyright","label":"Copyright"}]}}